. 2021 Feb 16;11(9):4050–4060. doi: 10.7150/thno.56211

Table 4.

Correlation between pre-therapeutic parameters and changes in TLP, MTV, and PSA. PFS, progression-free survival.

	ΔTLP		ΔMTV		ΔPSA
	r	p	r	p	r	p
PSA prior to tandem therapy	-0.05	0.86	-0.15	0.56	-0.08	0.75
PSA increase from previous cycle prior to tandem therapy	0.08	0.75	-0.04	0.89	-0.25	0.32
SUV_max of the most intense lesion prior to tandem therapy	0.12	0.65	0.21	0.42	0.10	0.69
SUV_peak of the most intense lesion prior to tandem therapy	0.13	0.62	0.20	0.44	0.11	0.67
TLP tumour load prior to tandem therapy	0.08	0.77	0.06	0.81	-0.17	0.51
MTV tumour load prior to tandem therapy	0.02	0.95	-0.01	0.96	-0.20	0.43
Administered ²²⁵Ac activity	0.12	0.65	0.11	0.67	-0.21	0.41
Administered ¹⁷⁷Lu activity	-0.09	0.72	-0.14	0.58	-0.22	0.40
Applied ²²⁵Ac/¹⁷⁷Lu activity ratio	0.18	0.49	0.20	0.45	-0.05	0.86
Cumulative ¹⁷⁷Lu activity prior to tandem therapy	-0.10	0.71	-0.21	0.43	-0.12	0.66
Time from initial diagnosis to tandem therapy	0.03	0.90	0.19	0.47	0.26	0.31
Time from initial diagnosis to castration resistance	0.00	0.10	0.13	0.61	0.20	0.44
PFS after chemotherapy (13/17 patients)	-0.26	0.40	-0.31	0.30	-0.16	0.61
Time from start of ¹⁷⁷Lu-PSMA-RLT to tandem therapy	-0.43	0.09	-0.44	0.08	-0.24	0.36